“We continue to make meaningful and measurable progress across our (Z)-endoxifen development strategy in oncology,” stated Steven Quay, Atossa Therapeutics (ATOS)’ Chairman and CEO. “Initiatives include enhanced efficiency, focus and financial discipline with our programs, and readiness as we work to evolve into a commercial company. With a strong balance sheet, a strategically focused team, and the true desire to provide a solution for the millions of women worldwide suffering from breast cancer, we believe we are well-positioned to execute on our planned upcoming IND submission and advance our clinical programs toward key value-creating milestones.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics Advances Breast Cancer Treatment with (Z)-Endoxifen Study
- Atossa Therapeutics Appoints New Chief Financial Officer
- Atossa Therapeutics appoints Mark Daniel as CFO
- Atossa Therapeutics advances global patent strategy for Z-Endoxifen
- Atossa Therapeutics management to meet virtually with Craig-Hallum